泌尿肿瘤学中的免疫检查点抑制剂：对生物标志物的迫切需求
Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers.
作者信息
Pichler Renate
机构信息
Department of Urology, Medical University Innsbruck, A-6020 Innsbruck, Austria.
出版信息
Cancers (Basel). 2020 Sep 27;12(10):2768. doi: 10.3390/cancers12102768.
Abstract
Bladder cancer and renal cell carcinoma (RCC) are the second and third most commonly diagnosed cancers in the field of uro-oncology [...].
摘要
膀胱癌和肾细胞癌（RCC）是泌尿肿瘤学领域中第二和第三大最常被诊断出的癌症[...]。
相似文献
1
Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers.
Cancers (Basel). 2020 Sep 27;12(10):2768. doi: 10.3390/cancers12102768.
2
[Renaissance of immuno-oncology for urological tumors : Current status].
Urologe A. 2016 May;55(5):621-6. doi: 10.1007/s00120-016-0107-4.
3
Checkpoint inhibition: new treatment options in urologic cancer.
Acta Clin Belg. 2017 Feb;72(1):24-28. doi: 10.1080/17843286.2016.1260890.
4
Application of Mass Spectrometry Imaging in Uro-Oncology: Discovering Potential Biomarkers.
Life (Basel). 2022 Mar 3;12(3):366. doi: 10.3390/life12030366.
5
Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Expert Rev Anticancer Ther. 2019 Mar;19(3):259-271. doi: 10.1080/14737140.2019.1573678. Epub 2019 Feb 4.
6
Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
Ochsner J. 2019 Summer;19(2):138-151. doi: 10.31486/toj.18.0015.
7
Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Med Sci Monit. 2017 Jul 11;23:3360-3366. doi: 10.12659/msm.902426.
8
Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19.
9
Recent advances in immuno-oncology and its application to urological cancers.
BJU Int. 2016 Oct;118(4):506-14. doi: 10.1111/bju.13518. Epub 2016 Jun 3.
10
Immune checkpoint inhibition for the treatment of renal cell carcinoma.
Expert Opin Biol Ther. 2020 Jan;20(1):83-94. doi: 10.1080/14712598.2020.1677601. Epub 2019 Oct 13.
引用本文的文献
1
Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis.
Dis Markers. 2022 Mar 14;2022:4033583. doi: 10.1155/2022/4033583. eCollection 2022.
2
Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.
Front Oncol. 2021 Mar 24;11:640150. doi: 10.3389/fonc.2021.640150. eCollection 2021.
本文引用的文献
1
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
2
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Clin Cancer Res. 2021 Jan 1;27(1):78-86. doi: 10.1158/1078-0432.CCR-20-2063. Epub 2020 Sep 1.
3
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0.
4
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Eur Urol. 2019 Sep;76(3):368-380. doi: 10.1016/j.eururo.2019.05.041. Epub 2019 Jun 21.
5
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
6
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
9
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
10
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.
Zotero 插件